

Johnson & Johnson
First Quarter 2026
Other Financial Disclosures
Table of Contents

<u>Table 1: Sales by Segment</u>	1
<u>Table 2: Sales by Geographic Area</u>	2
<u>Table 3: Sales of Key Products/Franchises</u>	3 - 7
<u>Table 4: Condensed Consolidated Statement of Earnings - QTD</u>	8
<u>Table 5: Non-GAAP Adjusted Operational Sales Growth - QTD</u>	9
<u>Table 6: Non-GAAP Adjusted Net Earnings</u>	10
<u>Table 7: Non-GAAP P&L by Segment Reconciliation 2026 - QTD</u>	11
<u>Table 8: Non-GAAP P&L by Segment Reconciliation 2025 - QTD</u>	12

Johnson & Johnson and Subsidiaries
Supplementary Sales Data

(Unaudited; Dollars in Millions)

FIRST QUARTER

	2026	2025	Total	Percent Change	
				Operations	Currency
Sales to customers by segment of business					
Innovative Medicine					
U.S.	\$ 8,871	8,092	9.6 %	9.6	-
International	6,555	5,781	13.4	4.3	9.1
	15,426	13,873	11.2	7.4	3.8
MedTech					
U.S.	4,459	4,213	5.9	5.9	-
International	4,177	3,807	9.7	3.2	6.5
	8,636	8,020	7.7	4.6	3.1
U.S.	13,330	12,305	8.3	8.3	-
International	10,732	9,588	11.9	3.9	8.0
Worldwide	\$ 24,062	21,893	9.9 %	6.4	3.5

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

Johnson & Johnson and Subsidiaries
Supplementary Sales Data

	FIRST QUARTER				
	2026	2025	Total	Percent Change	
				Operations	Currency
Sales to customers by geographic area					
U.S.	\$ 13,330	12,305	8.3 %	8.3	-
Europe	5,848	5,110	14.5	2.7	11.8
Western Hemisphere excluding U.S.	1,293	1,167	10.8	2.5	8.3
Asia-Pacific, Africa	3,591	3,311	8.5	6.1	2.4
International	10,732	9,588	11.9	3.9	8.0
Worldwide	\$ 24,062	21,893	9.9 %	6.4	3.5

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely

REPORTED SALES vs. PRIOR PERIOD (\$MM)

INNOVATIVE MEDICINE SEGMENT ⁽²⁾

ONCOLOGY

	<u>2026</u>	<u>2025</u>	<u>FIRST QUARTER</u>		
			<u>Reported</u>	<u>Operational</u> ⁽¹⁾	<u>Currency</u>
US	\$ 3,615	3,013	20.0%	20.0%	-
Intl	3,358	2,664	26.0%	15.3%	10.7%
WW	<u>6,973</u>	<u>5,678</u>	22.8%	17.8%	5.0%
<u>DARZALEX</u>					
US	2,208	1,829	20.7%	20.7%	-
Intl	1,756	1,409	24.7%	14.0%	10.7%
WW	<u>3,964</u>	<u>3,237</u>	22.5%	17.8%	4.7%
<u>CARVYKTI</u>					
US	433	318	36.2%	36.2%	-
Intl	164	51	*	*	*
WW	<u>597</u>	<u>369</u>	62.1%	57.4%	4.7%
<u>TECVAYLI</u>					
US	127	105	20.6%	20.6%	-
Intl	74	46	63.1%	52.1%	11.0%
WW	<u>202</u>	<u>151</u>	33.5%	30.1%	3.4%
<u>TALVEY</u>					
US	101	68	48.5%	48.5%	-
Intl	51	18	*	*	*
WW	<u>152</u>	<u>86</u>	76.7%	72.8%	3.9%
<u>RYBREVANT / LAZCLUZE</u>					
US	175	113	55.1%	55.1%	-
Intl	82	28	*	*	*
WW	<u>257</u>	<u>141</u>	82.7%	80.5%	2.2%
<u>ERLEADA</u>					
US	342	292	17.3%	17.3%	-
Intl	607	479	26.7%	15.5%	11.2%
WW	<u>949</u>	<u>771</u>	23.1%	16.2%	6.9%
<u>IMBRUVICA</u>					
US	143	235	(39.1)%	(39.1)%	-
Intl	517	474	9.1%	(1.4)%	10.5%
WW	<u>660</u>	<u>709</u>	(6.9)%	(13.9)%	7.0%
<u>OTHER ONCOLOGY</u> ⁽³⁾					
US	85	54	58.8%	58.8%	-
Intl	106	160	(33.9)%	(36.3)%	2.4%
WW	<u>192</u>	<u>214</u>	(10.6)%	(12.5)%	1.9%

See footnotes at end of schedule

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	FIRST QUARTER				
	<u>2026</u>	<u>2025</u>	<u>Reported</u>	<u>% Change Operational ⁽¹⁾</u>	<u>Currency</u>
IMMUNOLOGY					
US	\$ 1,855	2,196	(15.5)%	(15.5)%	-
Intl	1,524	1,510	0.9%	(6.4)%	7.3%
WW	<u>3,380</u>	<u>3,707</u>	(8.8)%	(11.8)%	3.0%
<u>TREMFYA</u>					
US	1,042	599	73.9%	73.9%	-
Intl	566	356	58.9%	46.8%	12.1%
WW	<u>1,608</u>	<u>956</u>	68.3%	63.8%	4.5%
<u>SIMPONI / SIMPONI ARIA</u>					
US	269	292	(7.8)%	(7.8)%	-
Intl	378	366	3.0%	(4.1)%	7.1%
WW	<u>647</u>	<u>659</u>	(1.7)%	(5.7)%	4.0%
<u>REMICADE</u>					
US	269	314	(14.4)%	(14.4)%	-
US Exports ⁽⁴⁾	18	10	78.6%	78.6%	-
Intl	136	143	(4.8)%	(10.5)%	5.7%
WW	<u>422</u>	<u>467</u>	(9.5)%	(11.2)%	1.7%
<u>STELARA</u>					
US	220	981	(77.6)%	(77.6)%	-
Intl	435	644	(32.4)%	(37.7)%	5.3%
WW	<u>656</u>	<u>1,625</u>	(59.7)%	(61.7)%	2.0%
<u>OTHER IMMUNOLOGY</u>					
US	38	1	*	*	-
Intl	9	0	*	*	*
WW	<u>46</u>	<u>1</u>	*	*	*
NEUROSCIENCE					
US	1,494	968	54.3%	54.3%	-
Intl	681	679	0.3%	(6.3)%	6.6%
WW	<u>2,175</u>	<u>1,647</u>	32.0%	29.3%	2.7%
<u>SPRAVATO</u>					
US	406	276	47.0%	47.0%	-
Intl	61	43	42.4%	28.7%	13.7%
WW	<u>468</u>	<u>320</u>	46.4%	44.5%	1.9%
<u>CAPLYTA ⁽⁵⁾</u>					
US	270	-	*	*	-
Intl	-	-	-	-	-
WW	<u>270</u>	<u>-</u>	*	*	-
<u>INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA</u>					
US	758	625	21.2%	21.2%	-
Intl	280	277	1.1%	(4.9)%	6.0%
WW	<u>1,038</u>	<u>903</u>	15.0%	13.2%	1.8%
<u>CONCERTA / Methylphenidate</u>					
US	22	38	(43.4)%	(43.4)%	-
Intl	115	110	4.3%	(0.6)%	4.9%
WW	<u>136</u>	<u>148</u>	(8.0)%	(11.7)%	3.7%
<u>OTHER NEUROSCIENCE</u>					
US	38	28	32.6%	32.6%	-
Intl	224	248	(9.7)%	(16.3)%	6.6%
WW	<u>262</u>	<u>277</u>	(5.4)%	(11.3)%	5.9%

See footnotes at end of schedule

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	FIRST QUARTER				
	<u>2026</u>	<u>2025</u>	<u>Reported</u>	<u>% Change</u> <u>Operational ⁽¹⁾</u>	<u>Currency</u>
<u>PULMONARY HYPERTENSION (PH)</u>					
US	\$ 831	744	11.7%	11.7%	-
Intl	304	281	8.2%	1.0%	7.2%
WW	<u>1,135</u>	<u>1,025</u>	10.7%	8.7%	2.0%
<u>UPTRAVI</u>					
US	385	365	5.4%	5.4%	-
Intl	98	86	14.3%	5.1%	9.2%
WW	<u>483</u>	<u>451</u>	7.1%	5.4%	1.7%
<u>OPSUMIT / OPSYNOVI</u>					
US	433	363	19.3%	19.3%	-
Intl	172	159	8.7%	1.7%	7.0%
WW	<u>606</u>	<u>522</u>	16.1%	14.0%	2.1%
<u>OTHER PULMONARY HYPERTENSION</u>					
US	12	15	(21.1)%	(21.1)%	-
Intl	34	37	(8.3)%	(11.8)%	3.5%
WW	<u>46</u>	<u>52</u>	(12.1)%	(14.5)%	2.4%
<u>INFECTIOUS DISEASES (ID)</u>					
US	342	315	8.6%	8.6%	-
Intl	547	487	12.2%	1.3%	10.9%
WW	<u>889</u>	<u>802</u>	10.8%	4.1%	6.7%
<u>EDURANT / rilpivirine</u>					
US	7	8	(13.1)%	(13.1)%	-
Intl	402	350	14.8%	3.2%	11.6%
WW	<u>409</u>	<u>358</u>	14.1%	2.8%	11.3%
<u>PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA</u>					
US	334	305	9.5%	9.5%	-
Intl	109	98	11.2%	0.7%	10.5%
WW	<u>443</u>	<u>403</u>	10.0%	7.4%	2.6%
<u>OTHER INFECTIOUS DISEASES</u>					
US	1	2	(56.9)%	(56.9)%	-
Intl	36	39	(8.3)%	(14.7)%	6.4%
WW	<u>37</u>	<u>41</u>	(10.4)%	(16.5)%	6.1%
<u>CARDIOVASCULAR / METABOLISM / OTHER (CVM)</u>					
US	734	855	(14.2)%	(14.2)%	-
Intl	142	158	(10.4)%	(17.5)%	7.1%
WW	<u>876</u>	<u>1,013</u>	(13.6)%	(14.7)%	1.1%
<u>XARELTO</u>					
US	642	690	(7.0)%	(7.0)%	-
Intl	-	-	-	-	-
WW	<u>642</u>	<u>690</u>	(7.0)%	(7.0)%	-
<u>OTHER</u>					
US	91	165	(44.5)%	(44.5)%	-
Intl	142	158	(10.4)%	(17.5)%	7.1%
WW	<u>233</u>	<u>323</u>	(27.8)%	(31.2)%	3.4%
<u>TOTAL PH, ID, CVM</u>					
US	1,907	1,914	(0.4)%	(0.4)%	-
Intl	993	926	7.1%	(2.0)%	9.1%
WW	<u>2,899</u>	<u>2,840</u>	2.1%	(0.9)%	3.0%
<u>TOTAL INNOVATIVE MEDICINE</u>					
US	8,871	8,092	9.6%	9.6%	-
Intl	6,555	5,781	13.4%	4.3%	9.1%
WW	<u>\$ 15,426</u>	<u>13,873</u>	11.2%	7.4%	3.8%

See footnotes at end of schedule

REPORTED SALES vs. PRIOR PERIOD (\$MM)

MEDTECH SEGMENT ⁽²⁾

CARDIOVASCULAR

	<u>2026</u>	<u>2025</u>	<u>% Change</u>		<u>Currency</u>
			<u>Reported</u>	<u>Operational</u> ⁽¹⁾	
US	1,399	1,261	10.9%	10.9%	-
Intl	978	842	16.1%	9.9%	6.2%
WW	<u>2,377</u>	<u>2,103</u>	13.0%	10.5%	2.5%

ELECTROPHYSIOLOGY

US	736	684	7.6%	7.6%	-
Intl	753	638	18.0%	11.7%	6.3%
WW	<u>1,489</u>	<u>1,323</u>	12.6%	9.5%	3.1%

ABIOMED

US	389	339	14.5%	14.5%	-
Intl	100	81	23.5%	13.9%	9.6%
WW	<u>488</u>	<u>420</u>	16.3%	14.4%	1.9%

SHOCKWAVE

US	242	206	17.8%	17.8%	-
Intl	63	52	21.3%	19.3%	2.0%
WW	<u>305</u>	<u>258</u>	18.5%	18.1%	0.4%

OTHER CARDIOVASCULAR

US	32	32	0.7%	0.7%	-
Intl	62	72	(13.4)%	(17.5)%	4.1%
WW	<u>94</u>	<u>103</u>	(9.1)%	(11.9)%	2.8%

SURGERY

US	1,046	1,002	4.4%	4.4%	-
Intl	1,465	1,394	5.1%	(1.1)%	6.2%
WW	<u>2,511</u>	<u>2,396</u>	4.8%	1.2%	3.6%

ADVANCED

US	477	457	4.2%	4.2%	-
Intl	646	616	4.9%	(1.0)%	5.9%
WW	<u>1,123</u>	<u>1,073</u>	4.6%	1.2%	3.4%

GENERAL

US	569	544	4.5%	4.5%	-
Intl	819	778	5.2%	(1.3)%	6.5%
WW	<u>1,388</u>	<u>1,323</u>	4.9%	1.1%	3.8%

See footnotes at end of schedule

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	FIRST QUARTER				
	2026	2025	% Change		
			Reported	Operational ⁽¹⁾	Currency
VISION					
US	579	566	2.4%	2.4%	-
Intl	785	713	10.1%	4.6%	5.5%
WW	<u>1,365</u>	<u>1,279</u>	6.7%	3.6%	3.1%
CONTACT LENSES / OTHER					
US	468	452	3.7%	3.7%	-
Intl	501	467	7.2%	1.7%	5.5%
WW	<u>969</u>	<u>919</u>	5.5%	2.7%	2.8%
SURGICAL					
US	111	114	(2.9)%	(2.9)%	-
Intl	285	246	15.6%	10.1%	5.5%
WW	<u>396</u>	<u>361</u>	9.7%	6.0%	3.7%
ORTHOPAEDICS					
US	1,435	1,384	3.7%	3.7%	-
Intl	948	857	10.6%	2.4%	8.2%
WW	<u>2,383</u>	<u>2,241</u>	6.3%	3.2%	3.1%
HIPS					
US	277	263	5.2%	5.2%	-
Intl	159	146	8.9%	0.3%	8.6%
WW	<u>436</u>	<u>409</u>	6.5%	3.5%	3.0%
KNEES					
US	239	231	3.3%	3.3%	-
Intl	181	158	14.6%	6.5%	8.1%
WW	<u>420</u>	<u>389</u>	7.9%	4.6%	3.3%
TRAUMA					
US	532	502	6.1%	6.1%	-
Intl	301	270	11.4%	3.1%	8.3%
WW	<u>833</u>	<u>772</u>	8.0%	5.0%	3.0%
SPINE, SPORTS & OTHER					
US	387	388	(0.1)%	(0.1)%	-
Intl	307	283	8.4%	0.7%	7.7%
WW	<u>694</u>	<u>671</u>	3.5%	0.2%	3.3%
TOTAL MEDTECH					
US	4,459	4,213	5.9%	5.9%	-
Intl	4,177	3,807	9.7%	3.2%	6.5%
WW	<u>\$ 8,636</u>	<u>8,020</u>	7.7%	4.6%	3.1%

Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely

* Percentage greater than 100% or not meaningful

(1) Operational growth excludes the effect of translational currency

(2) Unaudited

(3) Includes the sales of ZYTIGA which were previously disclosed separately

(4) Reported as U.S. sales

(5) Acquired with Intra-Cellular Therapies on April 2, 2025

Johnson & Johnson and Subsidiaries

Condensed Consolidated Statement of Earnings

(Unaudited; in Millions Except Per Share Figures)

FIRST QUARTER

	2026		2025		Percent Increase (Decrease)
	Amount	Percent to Sales	Amount	Percent to Sales	
Sales to customers	\$ 24,062	100.0	\$ 21,893	100.0	9.9
Cost of products sold	8,106	33.7	7,357	33.6	10.2
Gross Profit	15,956	66.3	14,536	66.4	9.8
Selling, marketing and administrative expenses	6,034	25.1	5,112	23.3	18.0
Research and development expense	3,527	14.7	3,225	14.7	9.4
In-process research and development impairments	36	0.1	-	-	
Interest (income) expense, net	43	0.2	(128)	(0.6)	
Other (income) expense, net	294	1.2	(7,321)	(33.4)	
Restructuring	32	0.1	17	0.1	
Earnings before provision for taxes on income	5,990	24.9	13,631	62.3	(56.1)
Provision for taxes on income	755	3.1	2,632	12.1	(71.3)
Net earnings	\$ 5,235	21.8	\$ 10,999	50.2	(52.4)
Net earnings per share (Diluted)	\$ 2.14		\$ 4.54		(52.9)
Average shares outstanding (Diluted)	2,445.2		2,423.8		
Effective tax rate	12.6 %		19.3 %		
Adjusted earnings before provision for taxes and net earnings (1)					
Earnings before provision for taxes on income	\$ 7,821	32.5	\$ 8,011	36.6	(2.4)
Net earnings	\$ 6,614	27.5	\$ 6,706	30.6	(1.4)
Net earnings per share (Diluted)	\$ 2.70		\$ 2.77		(2.5)
Effective tax rate	15.4 %		16.3 %		

(1) See Reconciliation of Non-GAAP Financial Measures.

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure

Adjusted Operational Sales Growth
FIRST QUARTER 2026 ACTUAL vs. 2025 ACTUAL

Segments			
	<u>Innovative Medicine</u>	<u>MedTech</u>	<u>Total</u>
WW As Reported	11.2%	7.7%	9.9%
U.S.	9.6%	5.9%	8.3%
International	13.4%	9.7%	11.9%
WW Currency	3.8	3.1	3.5
U.S.	-	-	-
International	9.1	6.5	8.0
WW Operational	7.4%	4.6%	6.4%
U.S.	9.6%	5.9%	8.3%
International	4.3%	3.2%	3.9%
Caplyta	(1.9)		(1.2)
U.S.	(3.3)		(2.2)
International	0.0		0.0
All Other Acquisitions and Divestitures (A&D)	0.1	0.1	0.1
U.S.	0.0	0.2	0.1
International	0.2	0.0	0.1
WW Adjusted Operational Ex A&D	5.6%	4.7%	5.3%
U.S.	6.3%	6.1%	6.2%
International	4.5%	3.2%	4.0%

Note: Percentages are based on actual, non-rounded figures and may not sum

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures

	First Quarter	
(Dollars in Millions Except Per Share Data)	2026	2025
Net Earnings, after tax- as reported	\$5,235	\$10,999
<i>Pre-tax Adjustments</i>		
Intangible Asset Amortization expense	1,247	1,120
Litigation related	330	(6,966)
Orthopaedics Separation related	119	-
Acquisition, integration and divestiture related	96	132
Restructuring related ¹	62	55
IPR&D impairments	36	-
(Gains)/losses on securities	(59)	39
<i>Tax Adjustments</i>		
Tax impact on special item adjustments ²	(424)	1,315
Tax legislation and other tax related	(28)	12
Adjusted Net Earnings, after tax	\$6,614	\$6,706
Average shares outstanding (Diluted)	2,445.2	2,423.8
Adjusted net earnings per share (Diluted)	\$2.70	\$2.77
Operational adjusted net earnings per share (Diluted)	\$2.57	

Notes:

¹ In fiscal 2023, the company initiated a restructuring program of its Orthopaedics franchise within the MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The restructuring expense of \$7 million in the fiscal first quarter of 2026 and \$55 million in the fiscal first quarter of 2025 primarily includes costs related to market and product exits. This program was substantially completed in Q4 2025.

In fiscal 2025, the company initiated a restructuring program of its Surgery franchise within the MedTech segment to simplify and focus operations by exiting certain non-strategic product lines and optimize select sites across the network. The restructuring expense of \$55 million in the fiscal first quarter of 2026 primarily includes costs related to product exits. This program is expected to be substantially completed by the end of fiscal year 2026.

² The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.

Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
\$ in Millions

Year to Date

	First Quarter Mar. 29, 2026 GAAP	Intangible asset amortization	Litigation related	In-process research and development impairments	Restructuring related	Acquisition, integration and divestiture related	(Loss)/gain on securities	Orthopaedics Separation Related	Tax legislation and other tax related	First Quarter Mar. 29, 2026 Non-GAAP
Innovative Medicine										
Cost of products sold	\$ 4,390	(763)				(10)				\$ 3,617
Selling, marketing and admin expenses	2,918									2,918
Research and development expense	2,813									2,813
Other segment items	(12)		(40)			(46)	55			(43)
Adjusted Income Before Tax by Segment	5,317	763	40	-	-	56	(55)	-	-	6,121
MedTech										
Cost of products sold	\$ 3,701	(484)			(25)					\$ 3,192
Selling, marketing and admin expenses	2,906									2,906
Research and development expense	714									714
Other segment items	76		41	(36)	(37)	(27)	4	(119)		(98)
Adjusted Income Before Tax by Segment	1,239	484	(41)	36	62	27	(4)	119	-	1,922
Expenses not allocated to segments										
Cost of products sold	\$ 15									\$ 15
Selling, marketing and admin expenses	210									210
Research and development expense	-									-
Other segment items	341		(331)			(13)				(3)
Adjusted Income Before Tax by Segment	(566)	-	331	-	-	13	-	-	-	(222)
Johnson & Johnson Consolidated										
Cost of products sold	\$ 8,106	(1,247)			(25)	(10)				\$ 6,824
Selling, marketing and admin expenses	6,034									6,034
Research and development expense	3,527									3,527
Other (Income) / Expense	294		(330)		(5)	(86)	59	(119)		(187)
In-process research and development impairments	36			(36)						-
Interest (Income)/Expense	43									43
Restructuring	32				(32)					-
Adjusted Income Before Tax	5,990	1,247	330	36	62	96	(59)	119	-	7,821
Provision for taxes on income	755	240	72	8	70	22	(13)	25	28	1,207
Net Earnings	\$ 5,235	1,007	258	28	(8)	74	(46)	94	(28)	6,614

Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
\$ in Millions

Year to Date

	First Quarter March 30, 2025 GAAP	Intangible asset amortization	Litigation related	Restructuring related	Acquisition, integration and divestiture related	(Loss)/gain on securities	Tax legislation and other tax related	First Quarter March 30, 2025 Non-GAAP
Innovative Medicine								
Cost of products sold	\$ 4,020	(649)						3,371
Selling, marketing and admin expenses	2,261							2,261
Research and development expense	2,548							2,548
Other segment items	(166)	-	-	-	(20)	(18)	-	(204)
Adjusted Income Before Tax by Segment	5,210	649	-	-	20	18	-	5,897

	First Quarter March 30, 2025 GAAP	Intangible asset amortization	Litigation related	Restructuring related	Acquisition, integration and divestiture related	(Loss)/gain on securities	Tax legislation and other tax related	First Quarter March 30, 2025 Non-GAAP
MedTech								
Cost of products sold	\$ 3,326	(471)		(8)	(52)			2,795
Selling, marketing and admin expenses	2,656							2,656
Research and development expense	677				(6)			671
Other segment items	(60)	-	-	(47)	(54)	(21)	-	(182)
Adjusted Income Before Tax by Segment	1,421	471	-	55	112	21	-	2,080

	First Quarter March 30, 2025 GAAP	Intangible asset amortization	Litigation related	Restructuring related	Acquisition, integration and divestiture related	(Loss)/gain on securities	Tax legislation and other tax related	First Quarter March 30, 2025 Non-GAAP
Expenses not allocated to segments								
Cost of products sold	\$ 11							11
Selling, marketing and admin expenses	195							195
Research and development expense								-
Other segment items	(7,206)	-	6,966	-	-	-	-	(240)
Adjusted Income Before Tax by Segment	7,000	-	(6,966)	-	-	-	-	34

	First Quarter March 30, 2025 GAAP	Intangible asset amortization	Litigation related	Restructuring related	Acquisition, integration and divestiture related	(Loss)/gain on securities	Tax legislation and other tax related	First Quarter March 30, 2025 Non-GAAP
Johnson & Johnson Consolidated								
Cost of products sold	\$ 7,357	(1,120)		(8)	(52)		-	6,177
Selling, marketing and admin expenses	5,112							5,112
Research and development expense	3,225				(6)			3,219
Other (Income) / Expense	(7,321)	-	6,966	(30)	(74)	(39)		(498)
In-process research and development impairments	-							-
Interest (Income)/Expense	(128)							(128)
Restructuring	17			(17)				-
Adjusted Income Before Tax	13,631	1,120	(6,966)	55	132	39	-	8,011
Provision for taxes on income	2,632	188	(1,553)	11	30	9	(12)	1,305
Net Earnings	10,999	932	(5,413)	44	102	30	12	6,706